Literature DB >> 17568245

Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients.

Chien-Fang Huang1, Tsai-Chung Li, Cheng-Chieh Lin, Chiu-Shong Liu, Hung-Chang Shih, Ming-May Lai.   

Abstract

BACKGROUND: Several lipid ratios may be predictors of coronary artery disease risk. We assessed the efficacy of Monascus purpureus Went rice (red yeast rice) on lowering lipid ratios. METHOD AND
RESULTS: We evaluated 79 hypercholesterolemic patients (aged 23-65 years) who received a twice-daily dose of either red yeast rice or a placebo at 600 mg for 8 weeks. The 8-week treatment with red yeast rice showed significantly greater reduction than the placebo treatment in low-density lipoprotein cholesterol levels, total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and apolipoprotein B/apolipoprotein A-I ratios.
CONCLUSIONS: Red yeast rice can reduce lipid ratios in hypercholesterolemic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568245     DOI: 10.1097/HJR.0b013e32801da137

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  10 in total

Review 1.  The role of red yeast rice for the physician.

Authors:  Ram Y Gordon; David J Becker
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

2.  No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and Lactobacillus casei in hyperlipidemic patients: A double-blind randomized controlled clinical trial.

Authors:  Chien-Ying Lee; Min-Chien Yu; Wu-Tsun Perng; Chun-Che Lin; Ming-Yung Lee; Ya-Lan Chang; Ya-Yun Lai; Yi-Ching Lee; Yu-Hsiang Kuan; James Cheng-Chung Wei; Hung-Che Shih
Journal:  Chin J Integr Med       Date:  2016-11-12       Impact factor: 1.978

3.  LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia.

Authors:  Nicolas Ogier; Marie-Josèphe Amiot; Stéphane Georgé; Matthieu Maillot; Cécilia Mallmann; Marie Maraninchi; Sophie Morange; Jean-François Lescuyer; Sébastien L Peltier; Nicolas Cardinault
Journal:  Eur J Nutr       Date:  2012-04-24       Impact factor: 5.614

4.  Monascus purpureus Went rice in nephrotic hyperlipidemia.

Authors:  O Gheith; H Sheashaa; M Sobh; M Abdelsalam; Z Shoeir
Journal:  Indian J Nephrol       Date:  2008-04

Review 5.  How do you treat patients with myalgia who take statins?

Authors:  Saadi A Siddiqi; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

6.  Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia.

Authors:  Osama Gheith; Hussein Sheashaa; Mohamed Abdelsalam; Zaki Shoeir; Mohamed Sobh
Journal:  Clin Exp Nephrol       Date:  2008-03-26       Impact factor: 2.801

7.  Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy.

Authors:  Donald I Abrams; Paul Couey; Starley B Shade; Mary Ellen Kelly; Nnemdi Kamanu-Elias; Paul Stamets
Journal:  BMC Complement Altern Med       Date:  2011-08-10       Impact factor: 3.659

8.  Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine.

Authors:  Bo Zhu; Fangyuan Qi; Jianjun Wu; Guoqing Yin; Jinwei Hua; Qiaoyan Zhang; Luping Qin
Journal:  Front Pharmacol       Date:  2019-12-02       Impact factor: 5.810

9.  Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin.

Authors:  Chia-Hao Chen; Yow-Shieng Uang; Shang-Ta Wang; Jyh-Chin Yang; Chun-Jung Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-14       Impact factor: 2.629

10.  A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.

Authors:  Yinhua Li; Long Jiang; Zhangrong Jia; Wei Xin; Shiwei Yang; Qiu Yang; Luya Wang
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.